Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030 [Gastrointestinal Cancer]
Conclusion Although liver cancer has long had some of the most rapidly increasing incidence rates, the decreasing rates seen among APIs, individuals younger than 65 years, and cohorts born after 1960 suggest that there will be declines in incidence of HCC in future years. Prevention efforts should be focused on individuals in the 1950 to 1959 birth cohorts, Hispanics, and blacks. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Petrick, Kelly, Altekruse, McGlynn, Rosenberg Tags: Incidence trends, Population and observational studies (SEER, WHI observational, etc.), Epidemiology, Diagnosis & Staging Gastrointestinal Cancer Source Type: research

Cancer and Fertility Program Improves Patient Satisfaction With Information Received [Treatment-Related Complications]
This study evaluated the program’s impact on patient satisfaction with information received. Patients and Methods Retrospective cross-sectional surveys assessed satisfaction before (cohort 1 [C1]) and after (cohort 2 [C2]) program initiation. Questionnaires were investigator-designed, gender-specific, and anonymous. Results Most C1 (150 males, 271 females) and C2 (120 males, 320 females) respondents were 2 years postdiagnosis; the most frequently reported cancers were testicular, breast, and lymphoma. A significant difference in satisfaction with the amount of information received was seen between C1 and C2. For ma...
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Kelvin, Thom, Benedict, Carter, Corcoran, Dickler, Goodman, Margolies, Matasar, Noy, Goldfarb Tags: Supportive Care, Quality of Life, Quality of Care Treatment-Related Complications Source Type: research

Risk of Adverse Health and Social Outcomes Up to 50 Years After Wilms Tumor: The British Childhood Cancer Survivor Study [Epidemiology]
Conclusion Between 30 and 50 years from diagnosis, survivors of WT are at a substantially increased risk of premature mortality, and 75% of excess deaths were accounted for by SPNs and cardiac diseases. Radiotherapy exposure was a risk factor for both outcomes. The proportion of patients with WT who are exposed to radiotherapy has reduced substantially in recent decades because of initiatives such as the SIOP WT 2001 clinical trial, which sought to reduce late effects; however, the majority of current survivors, who are at least 30 years from diagnosis, received radiotherapy. Surveillance of this group should focus on SPNs...
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Wong, Reulen, Winter, Guha, Fidler, Kelly, Lancashire, Pritchard-Jones, Jenkinson, Sugden, Levitt, Frobisher, Hawkins Tags: Population and observational studies (SEER, WHI observational, etc.), Epidemiology Source Type: research

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer [Phase I and Clinical Pharmacology]
Purpose The primary objective was to determine safety, toxicity, and a recommended phase II dose regimen of LY2606368, an inhibitor of checkpoint kinase 1, as monotherapy. Patients and Methods This phase I, nonrandomized, open-label, dose-escalation trial used a 3 + 3 dose-escalation scheme and included patients with advanced solid tumors. Intravenous LY2606368 was dose escalated from 10 to 50 mg/m2 on schedule 1 (days 1 to 3 every 14 days) or from 40 to 130 mg/m2 on schedule 2 (day 1 every 14 days). Safety measures and pharmacokinetics were assessed, and pharmacodynamics were measured in blood, hair follicles, and circul...
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Hong, Infante, Janku, Jones, Nguyen, Burris, Naing, Bauer, Piha-Paul, Johnson, Kurzrock, Golden, Hynes, Lin, Lin, Bendell Tags: Phase I and Clinical Pharmacology, Genitourinary, H&N, Lung, Other, Phase I and Clinical Pharmacology Source Type: research

Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma [Clinical Trials]
Conclusion Single-agent temsirolimus at a weekly dose of 75 mg was found to be active in relapsed/refractory patients with PCNSL; however, responses were usually short lived. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Korfel, Schlegel, Herrlinger, Dreyling, Schmidt, von Baumgarten, Pezzutto, Grobosch, Kebir, Thiel, Martus, Kiewe Tags: Brain Tumors Clinical Trials Source Type: research

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991 [Radiation Oncology]
Purpose Up to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone–releasing hormone agonist) to primary radiotherapy (RT) for intermediate- or high-risk localized prostate cancer. Patients and Methods A total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) ≥ 10 ng/mL or Gleason ≥ 7, or (2) cT2a (International Union Against Cancer TN...
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Bolla, Maingon, Carrie, Villa, Kitsios, Poortmans, Sundar, van der Steen-Banasik, Armstrong, Bosset, Herrera, Pieters, Slot, Bahl, Ben-Yosef, Boehmer, Scrase, Renard, Shash, Coens, van den Bergh, Collette Tags: Radiation, Combined Modality Therapy, Radiation Oncology Source Type: research

Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein [Melanoma]
Purpose To evaluate for an association between 25-hydroxyvitamin D levels (vitamin D) and outcome measures in patients with melanoma after evaluation is controlled for systemic inflammatory response (SIR) on the basis of simultaneous C-reactive protein (CRP) measurement. Materials and Methods Plasma samples from 1,042 prospectively observed patients with melanoma were assayed for vitamin D and CRP. The associations of demographics and CRP with vitamin D were determined, followed by a determination of the association between vitamin D and stage and outcome measures from the date of blood draw. The vitamin D level was consi...
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Fang, Sui, Wang, Liu, Chiang, Ross, Gershenwald, Cormier, Royal, Lucci, Wargo, Hu, Gardner, Reveille, Bassett, Wei, Amos, Lee Tags: Epidemiology Melanoma Source Type: research

Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer [Health Services and Outcomes]
Conclusion Patients with cancer and limited financial reserves are more likely to have higher symptom burden and decreased QOL. Assessment of financial reserves may help identify patients who need intensive support. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Lathan, Cronin, Tucker-Seeley, Zafar, Ayanian, Schrag Tags: Quality of Care, Outcomes Research, Quality of Life Health Services and Outcomes Source Type: research

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer [Rapid Communication]
Conclusion The addition of SIRT to FOLFOX-based first-line chemotherapy in patients with liver-dominant or liver-only metastatic colorectal cancer did not improve PFS at any site but significantly delayed disease progression in the liver. The safety profile was as expected and was consistent with previous studies. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: van Hazel, Heinemann, Sharma, Findlay, Ricke, Peeters, Perez, Robinson, Strickland, Ferguson, Rodriguez, Kroning, Wolf, Ganju, Walpole, Boucher, Tichler, Shacham-Shmueli, Powell, Eliadis, Isaacs, Price, Moeslein, Taieb, Bower, Gebski, Van Buskirk, Cade, T Tags: Clinical Trials, Radiation, Chemotherapy, Combined Modality, Radiation, Chemotherapy, Combined Modality, Radiation Oncology, Rapid Communications, Interventional Radiology Source Type: research

Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer [ONCOLOGY GRAND ROUNDS]
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 71-year-old man was seen by his primary care physician for routine evaluation in early 2015. On digital...
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Dosoretz, Yu Tags: Oncology Grand Rounds Source Type: research

Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Pollack, Abramowitz Tags: Radiation, Systemic Therapy, Combined Modality Therapy EDITORIALS Source Type: research

Vitamin D and Melanoma: What Do We Tell Our Patients? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Sondak, McIver, Kanetsky Tags: Behavioral and Lifestyle Risk Factors, Epidemiology, Diagnosis & Staging, Surgical Oncology EDITORIALS Source Type: research

Financial Strain and Cancer Outcomes [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Kaplan, Milstein Tags: Behavioral and Lifestyle Risk Factors, Population and observational studies (SEER, WHI observational, etc.), Epidemiology, Epidemiology EDITORIALS Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Ventriculitis Caused by Primary T-Cell CNS Lymphoma in an Immunocompetent Patient [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Nigo, Richardson, Azizi, Cohen, Shapira Tags: Lymphoma, Diagnosis & Staging, Brain Tumors DIAGNOSIS IN ONCOLOGY Source Type: research

Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Falchook, Ordonez, Bastida, Stephens, Miller, Gaido, Jackson, Karp Tags: Chemotherapy DIAGNOSIS IN ONCOLOGY Source Type: research

Adult Onset Primary Pineal Rhabdomyosarcoma [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 10, 2016 Category: Cancer & Oncology Authors: Scull, Amar, Feiz-Erfan, Dave, Gridley Tags: Epidemiology, Diagnosis & Staging, Surgery, Combined Modality DIAGNOSIS IN ONCOLOGY Source Type: research

Reply to N. Lowy et al and to J. Dhanda et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Hurria, Levit, Dale, Mohile, Muss, Fehrenbacher, Magnuson, Lichtman, Bruinooge, Soto-Perez-de-Celis, Tew, Postow, Cohen Tags: CORRESPONDENCE Source Type: research

Better Evidence About Older Adults With Cancer Will Not Improve Survival Rates Alone; Clinicians Need More Support [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Dhanda, O'Sullivan Tags: CORRESPONDENCE Source Type: research

US Food and Drug Administration and Representation of Older Adults in Clinical Trials [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Lowy, Whyte Tags: CORRESPONDENCE Source Type: research

Reply to C. Cozzarini et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Ghadjar, Hayoz, Bernhard, Zwahlen, Aebersold Tags: CORRESPONDENCE Source Type: research

Dose Escalation in Salvage Radiation Therapy and Urinary Toxicity: A Small Price to Pay for a Significant Prospective Benefit [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Cozzarini, Briganti, Fossati, Montorsi, Di Muzio, Fiorino Tags: CORRESPONDENCE Source Type: research

Reply to M. Minden [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Ballman Tags: CORRESPONDENCE Source Type: research

Is It Time to Redefine Prognostic and Predictive in Oncology? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Minden Tags: CORRESPONDENCE Source Type: research

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression [ASCO SPECIAL ARTICLE]
Purpose To update the ASCO adjuvant endocrine therapy guideline based on emerging data concerning the benefits and risks of ovarian suppression in addition to standard adjuvant therapy in premenopausal women with estrogen receptor–positive breast cancer. Methods ASCO convened an Update Panel and conducted a systematic review of randomized clinical trials investigating ovarian suppression. Results Two trials investigating the addition of ovarian suppression to tamoxifen did not show an overall clinical benefit for ovarian suppression. Nonetheless, the addition of ovarian suppression to standard adjuvant therapy with...
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Burstein, Lacchetti, Anderson, Buchholz, Davidson, Gelmon, Giordano, Hudis, Solky, Stearns, Winer, Griggs Tags: Epidemiology, Hormonal Therapy, ASCO Guidelines ASCO SPECIAL ARTICLE Source Type: research

Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition [REVIEW ARTICLE]
Purpose Non–small-cell lung cancer (NSCLC) is globally prevalent and associated with high rates of mortality. Immune checkpoint pathways are often exploited by tumors to evade immunity-mediated destruction, and checkpoint inhibitors can reactivate tumor-related immune responses. This review considers available clinical evidence for the use of checkpoint inhibitors in the treatment of second-line advanced NSCLC. Methods Our systematic search revealed 20 clinical trials evaluating checkpoint inhibitors in the second-line setting, three of which were randomized trials comparing programmed cell death protein 1 and progr...
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Melosky, Chu, Juergens, Leighl, McLeod, Hirsh Tags: Chemotherapy, Basic Science, Pathology, Lung, Immunology/Immunobiology REVIEW ARTICLE Source Type: research

Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas [Urologic Oncology]
This study evaluated efficacy and biomarkers of bevacizumab activity for NF2-associated progressive and symptomatic VSs. Patients and Methods Bevacizumab 7.5 mg/kg was administered every 3 weeks for 46 weeks, followed by 24 weeks of surveillance after treatment with the drug. The primary end point was hearing response defined by word recognition score (WRS). Secondary end points included toxicity, tolerability, imaging response using volumetric magnetic resonance imaging analysis, durability of response, and imaging and blood biomarkers. Results Fourteen patients (estimated to yield> 90% power to detect an alternative...
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Blakeley, Ye, Duda, Halpin, Bergner, Muzikansky, Merker, Gerstner, Fayad, Ahlawat, Jacobs, Jain, Zalewski, Dombi, Widemann, Plotkin Tags: Clinical Trials, Brain Tumors, Translational Oncology, Rare tumor types, MRI, Angiogenesis, Neuro Urologic Oncology Source Type: research

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma [Urologic Oncology]
Purpose To the best of our knowledge, this study is the first to compare dual inhibition of PI3K/mammalian target of rapamycin (mTOR) by apitolisib (GDC-0980) against single inhibition of mTORC1 by everolimus in metastatic renal cell carcinoma (mRCC). Patients and Methods Patients with clear-cell mRCC who progressed on or after vascular endothelial growth factor–targeted therapy were randomly assigned to apitolisib 40 mg once per day or to everolimus 10 mg once per day. End points included progression-free survival, safety, overall survival, and objective response rate. Biomarker assessments were conducted. Results...
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Powles, Lackner, Oudard, Escudier, Ralph, Brown, Hawkins, Castellano, Rini, Staehler, Ravaud, Lin, OKeeffe, Wang, Lu, Spoerke, Huw, Byrtek, Zhu, Ware, Motzer Tags: Clinical Trials, Translational Oncology Urologic Oncology Source Type: research

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer [Urologic Oncology]
Purpose Reports have suggested that metastatic site is an important predictor of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these were based on a limited number of patients. We investigate the impact of site of metastases on OS of a substantial sample of men with mCRPC who received docetaxel chemotherapy in nine phase III trials. Patients and Methods Individual patient data from 8,820 men with mCRPC enrolled onto nine phase III trials were combined. Site of metastases was categorized as lymph node (LN) only, bone with or without LN (with no visceral metastases), any lung...
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Halabi, Kelly, Ma, Zhou, Solomon, Fizazi, Tangen, Rosenthal, Petrylak, Hussain, Vogelzang, Thompson, Chi, de Bono, Armstrong, Eisenberger, Fandi, Li, Araujo, Logothetis, Quinn, Morris, Higano, Tannock, Small Tags: Prognostic Studies Urologic Oncology Source Type: research

National Trends in Nonoperative Management of Rectal Adenocarcinoma [Gastrointestinal Cancer]
Conclusion NOM demonstrates promise for the treatment of rectal cancer; currently, however, the most appropriate strategy is to pursue this approach with well-informed patients in the context of a clinical trial. We observed evidence of increasing NOM use, with this increase occurring more frequently in black and uninsured/Medicaid patients, raising concern that increased NOM use may actually represent increasing disparities in rectal cancer care rather than innovation. Further studies are needed to assess survival differences by treatment strategy. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Ellis, Samuel, Stitzenberg Tags: Population and observational studies (SEER, WHI observational, etc.), Combined Modality, Quality of Care Gastrointestinal Cancer Source Type: research

Racial/Ethnic Differences in Adverse Outcomes Among Childhood Cancer Survivors: The Childhood Cancer Survivor Study [Cancer Related Complications]
Conclusion By and large, NHB and Hispanic childhood cancer survivors experience a comparable burden of morbidity and mortality to their NHW counterparts. The few differences in risk were explained by the racial/ethnic differences in socioeconomic status and/or cardiovascular risk factors. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Liu, Leisenring, Ness, Robison, Armstrong, Yasui, Bhatia Tags: Long Term Survival & Late Effects, Outcomes Research Cancer Related Complications Source Type: research

Cardiovascular Disease Risk Profiles in Survivors of Adolescent and Young Adult (AYA) Cancer: The Kaiser Permanente AYA Cancer Survivors Study [Epidemiology]
Conclusion Survivors of AYA cancer are at increased risk for developing CVD. Survival after CVD onset is compromised, and CVRFs are independent modifiers of CVD risk. These data form the basis for identifying high-risk individuals and proactive management of CVRFs. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Chao, Xu, Bhatia, Cooper, Brar, Wong, Armenian Tags: Epidemiology Source Type: research

Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227 [Neurooncology]
Conclusion This regimen is safe, with the best 2-year OS and PFS achieved in any Radiation Therapy Oncology Group primary CNS lymphoma trial. Randomized trials that incorporate this regimen are needed to determine its efficacy compared with other strategies. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Glass, Won, Schultz, Brat, Bartlett, Suh, Werner-Wasik, Fisher, Liepman, Augspurger, Bokstein, Bovi, Solhjem, Mehta Tags: Clinical Trials, Brain Tumors, Radiation, Chemotherapy Neurooncology Source Type: research

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial [Neurooncology]
Purpose In patients with newly diagnosed glioblastoma that harbors a nonmethylated O6-methylguanine–DNA methyltransferase promotor, standard temozolomide (TMZ) has, at best, limited efficacy. The GLARIUS trial thus explored bevacizumab plus irinotecan (BEV+IRI) as an alternative to TMZ. Patients and Methods In this phase II, unblinded trial 182 patients in 22 centers were randomly assigned 2:1 to BEV (10 mg/kg every 2 weeks) during radiotherapy (RT) followed by maintenance BEV (10 mg/kg every 2 weeks) plus IRI(125 mg/m2 every 2 weeks) or to daily TMZ (75 mg/m2) during RT followed by six courses of TMZ (150-200 mg/m2...
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Herrlinger, Schafer, Steinbach, Weyerbrock, Hau, Goldbrunner, Friedrich, Rohde, Ringel, Schlegel, Sabel, Ronellenfitsch, Uhl, Maciaczyk, Grau, Schnell, Hanel, Krex, Vajkoczy, Gerlach, Kortmann, Mehdorn, Tuttenberg, Mayer-Steinacker, Fietkau, Brehmer, Mack Tags: Brain Tumors, Chemotherapy, MRI Neurooncology Source Type: research

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial [Breast Cancer]
Conclusion Overall, OFS added to tamoxifen resulted in worse endocrine symptoms and sexual functioning during the first 2 years of treatment, with variable magnitudes of treatment differences. Short-term differences in symptom-specific QoL, treatment burden, and coping effort between treatment groups were less pronounced for patients with prior chemotherapy, the cohort that benefited most from OFS in terms of disease control. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Ribi, Luo, Bernhard, Francis, Burstein, Ciruelos, Bellet, Pavesi, Lluch, Visini, Parmar, Tondini, Kerbrat, Perello, Neven, Torres, Lombardi, Puglisi, Karlsson, Ruhstaller, Colleoni, Coates, Goldhirsch, Price, Gelber, Regan, Fleming Tags: Hormonal Therapy, Quality of Life, Menopausal Symptoms Breast Cancer Source Type: research

Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole [Rapid Communications]
Purpose This prospective study assessed the impact of 2 years of aromatase inhibitor (AI) therapy on the incidence of ovarian function recovery (OFR) in women age 40 to 49 with estrogen receptor–positive breast cancer who were premenopausal at diagnosis and who underwent chemotherapy-induced amenorrhea during adjuvant treatment. Patients and Methods Women age 40 to 49 with estrogen receptor–positive breast cancer who had ceased menstruating with adjuvant cyclophosphamide-based chemotherapy, had postmenopausal serum estradiol (E2), and had received tamoxifen for ≥ 1 year were treated with letrozole (2.5 mg) ...
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Krekow, Hellerstedt, Collea, Papish, Diggikar, Resta, Vukelja, Holmes, Reddy, Asmar, Wang, Fox, Peck, OShaughnessy Tags: Hormonal Therapy, Rapid Communications Source Type: research

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy [Rapid Communications]
Purpose To describe estradiol (E2), estrone (E1), and estrone sulfate (E1S) levels during the first year of monthly triptorelin plus exemestane or tamoxifen and to assess possible suboptimal suppression while receiving exemestane plus triptorelin. Patients and Methods Premenopausal patients with early breast cancer on the Suppression of Ovarian Function Trial who selected triptorelin as the ovarian suppression method and were randomly assigned to exemestane plus triptorelin or tamoxifen plus triptorelin were enrolled until the target population of 120 patients was reached. Blood sampling time points were 0, 3, 6, 12, 18, ...
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Bellet, Gray, Francis, Lang, Ciruelos, Lluch, Climent, Catalan, Avella, Bohn, Gonzalez-Martin, Ferrer, Catalan, Azaro, Rajasekaran, Morales, Vazquez, Fleming, Price, Regan Tags: Hormonal Therapy, Rapid Communications Source Type: research

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Dowsett, Lonning, Davidson Tags: Hormonal Therapy COMMENTS AND CONTROVERSIES Source Type: research

Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer? [ONCOLOGY GRAND ROUNDS]
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 36-year-old premenopausal woman had been diagnosed with stage III breast cancer. After an initial biops...
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Papakonstantinou, Foukakis, Rodriguez-Wallberg, Bergh Tags: Oncology Grand Rounds Source Type: research

At the Heart of Adolescent and Young Adult Cancer Survivorship [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Baassiri, Mulrooney Tags: Long Term Survival & Late Effects EDITORIALS Source Type: research

Antiangiogenic Therapy for Glioblastoma: Complex Biology and Complicated Results [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Gilbert Tags: EDITORIALS Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Intralesional Methotrexate for Treatment of Invasive Squamous Cell Carcinomas in a Patient Taking Vemurafenib for Treatment of Metastatic Melanoma [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Moye, Clark, Legler, Milhem, Van Beek Tags: Chemotherapy, Non-Melanoma Skin Cancer DIAGNOSIS IN ONCOLOGY Source Type: research

Molecular Response of e19a2 BCR-ABL1 Chronic Myeloid Leukemia With Double Philadelphia Chromosome to Dasatinib [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Ikeda, Harada-Shirado, Matsumoto, Noji, Ogawa, Takeishi Tags: Diagnosis & Staging, Chemotherapy, Biological Therapy DIAGNOSIS IN ONCOLOGY Source Type: research

NUT Midline Carcinoma Masquerading As a Thymic Carcinoma [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Gokmen-Polar, Kesler, Loehrer, Badve Tags: Unknown Primary Site and Rare Cancers DIAGNOSIS IN ONCOLOGY Source Type: research

Reply to G. Nasti and A. Ottaiano and to A. Avallone and A. Budillon [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Modest, Held, Heinemann Tags: CORRESPONDENCE Source Type: research

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Avallone, Budillon Tags: CORRESPONDENCE Source Type: research

Best Sequence Therapy in RAS Wild-Type Metastatic Colorectal Cancer: Waiting for Randomized Crossover Clinical Trials [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Nasti, Ottaiano Tags: CORRESPONDENCE Source Type: research

Reply to A. Wong et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Chiou, Burotto Tags: CORRESPONDENCE Source Type: research

Integration of Immuno-Oncology and Palliative Care [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Wong, Fullerton, Spruyt, Brady, McArthur, Sandhu Tags: CORRESPONDENCE Source Type: research